Covered recipient · General Payments record
JAMES A TUMLIN
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$49,854.48
80 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $15,125.00 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,080.00 | 10 |
| Travel and Lodging | $11,526.77 | 17 |
| Consulting Fee | $5,125.00 | 2 |
| Food and Beverage | $2,997.71 | 47 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| CALLIDITAS THERAPEUTICS US INC. | $30,677.96 | 35 |
| Travere Therapeutics, Inc. | $10,389.15 | 12 |
| Aurinia Pharma U.S., Inc. | $4,565.13 | 8 |
| Alexion Pharmaceuticals, Inc. | $2,680.00 | 1 |
| ARGENX US, INC. | $625.00 | 1 |
| Mallinckrodt Hospital Products Inc. | $514.32 | 6 |
| Novartis Pharmaceuticals Corporation | $156.83 | 9 |
| AstraZeneca Pharmaceuticals LP | $103.95 | 2 |
| Amgen Inc. | $48.95 | 1 |
| GlaxoSmithKline, LLC. | $30.12 | 2 |
| Otsuka America Pharmaceutical, Inc. | $22.60 | 1 |
| Alnylam Pharmaceuticals Inc. | $21.93 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.54 | 1 |
Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAMES A TUMLIN
NPI 1467418053 · CMS profile ID 156467
Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
LAWRENCEVILLE, GA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1467418053?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAMES A TUMLIN, NPI 1467418053, CMS profile ID 156467. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467418053?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JAMES A TUMLIN, NPI 1467418053, CMS profile ID 156467. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467418053?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JAMES A TUMLIN, NPI 1467418053, CMS profile ID 156467, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1467418053?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
80 matching records · $49,854.48 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–80 of 80.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | $27.96 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149919322 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $104.26 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141513245 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.54 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118020004 | CMS |
| AstraZeneca Pharmaceuticals LP | $80.35 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105878727 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $15.66 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141512345 | CMS |
| Aurinia Pharma U.S., Inc. | $150.00 | 03/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150693667 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $145.00 | 03/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141512183 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $121.12 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141512145 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $79.96 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141512147 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $79.96 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141512149 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $79.96 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141512151 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $79.96 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141512153 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $179.64 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141512155 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $74.56 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141511899 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $51.18 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141511901 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $165.00 | 03/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141511903 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $310.94 | 03/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141511905 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $489.20 | 03/20/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141511731 | CMS |
| Alnylam Pharmaceuticals Inc. | $21.93 | 03/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125822509 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $48.44 | 03/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141511285 | CMS |
| Travere Therapeutics, Inc. | $506.15 | 02/06/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149919337 | CMS |
| Travere Therapeutics, Inc. | $2,000.00 | 02/06/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149919356 | CMS |
| Travere Therapeutics, Inc. | $177.26 | 01/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149919329 | CMS |
| Travere Therapeutics, Inc. | $1,106.71 | 01/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149919352 | CMS |
| Travere Therapeutics, Inc. | $22.79 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149919318 | CMS |
| Travere Therapeutics, Inc. | $399.84 | 01/16/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149919333 | CMS |
| Travere Therapeutics, Inc. | $3,100.16 | 01/16/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149919360 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $31.51 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141507892 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $32.00 | 01/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141507894 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $547.80 | 01/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141507896 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,261.27 | 3 |
| PY2025 | Principal investigator | $4,834,551.62 | 45 |
| PY2024 | Principal investigator | $3,444,563.66 | 40 |
| PY2023 | Principal investigator | $5,928,056.97 | 58 |
| PY2022 | Principal investigator | $3,057,107.35 | 103 |
| PY2021 | Principal investigator | $761,619.26 | 169 |
| PY2020 | Recipient | $18,821.80 | 4 |
| PY2020 | Principal investigator | $705,471.69 | 163 |
| PY2019 | Principal investigator | $592,888.85 | 247 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
48 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | CSL Behring | $25,228.00 | 12/29/2025 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252675764 |
| Principal investigator 1 | CSL Behring | $849.68 | 12/18/2025 | Non-covered Recipient Entity Georgia Nephrology | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252668562 |
| Principal investigator 1 | Humacyte Global, Inc. | $16,091.00 | 12/01/2025 | Non-covered Recipient Entity NephroNet CRO LLC | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | No dispute reported | 06/30/2026 | 1254959485 |
| Principal investigator 1 | Humacyte Global, Inc. | $15,841.15 | 12/01/2025 | Non-covered Recipient Entity NephroNet CRO LLC | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | No dispute reported | 06/30/2026 | 1254959489 |
| Principal investigator 1 | Genentech, Inc. | $9,675.00 | 11/21/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LLC | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211610839 |
| Principal investigator 1 | CSL Behring | $116.77 | 10/29/2025 | Non-covered Recipient Entity Georgia Nephrology | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252668560 |
| Principal investigator 1 | Genentech, Inc. | $23,430.71 | 10/28/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LLC | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211610834 |
| Principal investigator 1 | Humacyte Global, Inc. | $4,722.73 | 10/09/2025 | Non-covered Recipient Entity NephroNet CRO LLC | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | No dispute reported | 06/30/2026 | 1254959481 |
| Principal investigator 1 | Humacyte Global, Inc. | $28,980.02 | 10/08/2025 | Non-covered Recipient Entity NephroNet CRO LLC | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | No dispute reported | 06/30/2026 | 1254959341 |
| Principal investigator 1 | Humacyte Global, Inc. | $22,841.23 | 10/08/2025 | Non-covered Recipient Entity NephroNet CRO LLC | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | No dispute reported | 06/30/2026 | 1254959483 |
| Principal investigator 1 | CSL Behring | $94.69 | 10/07/2025 | Non-covered Recipient Entity Georgia Nephrology | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252668558 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $18,002.58 | 09/26/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LAWRENCEVILLE BILLING OFFICE | A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy | No dispute reported | 06/30/2026 | 1214124086 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $634,216.41 | 09/15/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY RESEARCH INSTITUTE | An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy | No dispute reported | 06/30/2026 | 1190310534 |
| Principal investigator 1 | CSL Behring | $90.79 | 09/10/2025 | Non-covered Recipient Entity Georgia Nephrology | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252668556 |
| Principal investigator 1 | CSL Behring | $548.15 | 09/08/2025 | Non-covered Recipient Entity Georgia Nephrology | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252668554 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $16,498.44 | 09/04/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY, LLC | A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | No dispute reported | 06/30/2026 | 1185551719 |
| Principal investigator 1 | Genentech, Inc. | $3,046.00 | 08/27/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LLC | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211610830 |
| Principal investigator 1 | Humacyte Global, Inc. | $16,557.74 | 08/25/2025 | Non-covered Recipient Entity NephroNet CRO LLC | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | No dispute reported | 06/30/2026 | 1254959487 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,500.00 | 08/19/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY RESEARCH INSTITUTE | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy | No dispute reported | 06/30/2026 | 1190310538 |
| Principal investigator 1 | CSL Behring | $16.71 | 08/11/2025 | Non-covered Recipient Entity Georgia Nephrology | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252668552 |
| Principal investigator 1 | CSL Behring | $250.38 | 07/22/2025 | Non-covered Recipient Entity Georgia Nephrology | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252668550 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $32,090.05 | 07/18/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY | a phase 3,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin a nephropathy IgAN | No dispute reported | 06/30/2026 | 1185551711 |
| Principal investigator 1 | Genentech, Inc. | $1,018.00 | 07/11/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LLC | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211610825 |
| Principal investigator 1 | Humacyte Global, Inc. | $5,200.68 | 07/02/2025 | Non-covered Recipient Entity NephroNet CRO LLC | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | No dispute reported | 06/30/2026 | 1254959479 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,000.00 | 07/01/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LLC | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy | No dispute reported | 06/30/2026 | 1190311549 |
| Principal investigator 1 | CSL Behring | $1,085.91 | 06/13/2025 | Non-covered Recipient Entity Georgia Nephrology | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252668548 |
| Principal investigator 1 | Mallinckrodt Hospital Products Inc. | $170,700.00 | 04/30/2025 | Non-covered Recipient Entity NEPHRONET INC | COMPARATIVE SAFETY AND EFFICACY OF ACTHAR GEL ALONE OR IN COMBINATION WITH ORAL TACROLIMUS TO REDUCING PROTEINURIA IN PATIENTS WITH IDIOPATHIC FIBRILLARY GLOMERULOPATHY | No dispute reported | 06/30/2026 | 1212110460 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $149,982.69 | 04/04/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY RESEARCH INSTITUTE | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function | No dispute reported | 06/30/2026 | 1190310528 |
| Principal investigator 1 | Genentech, Inc. | $12,979.00 | 04/01/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LLC | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211610822 |
| Recipient | F. Hoffmann-La Roche AG | $2,271.59 | 03/31/2025 | Covered Recipient Physician | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211536255 |
| Recipient | F. Hoffmann-La Roche AG | $234.86 | 03/31/2025 | Covered Recipient Physician | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211536259 |
| Recipient | F. Hoffmann-La Roche AG | $754.82 | 03/31/2025 | Covered Recipient Physician | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211536264 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $317,811.81 | 03/20/2025 | Non-covered Recipient Entity NEPHRONET | A ProsPective Open-Labeled Study of Anifrolumab in the Treatment of Collapsing Variant and APOL-1 Positive FSGS PROPOSAL Study | No dispute reported | 06/30/2026 | 1185551714 |
| Principal investigator 1 | CSL Behring | $1,850.36 | 03/05/2025 | Non-covered Recipient Entity Georgia Nephrology | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252668546 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $373,377.20 | 03/04/2025 | Non-covered Recipient Entity NEPHRONET | A ProsPective Open-Labeled Study of Anifrolumab in the Treatment of Collapsing Variant and APOL-1 Positive FSGS PROPOSAL Study | No dispute reported | 06/30/2026 | 1185551717 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,436.40 | 03/03/2025 | Non-covered Recipient Entity Georgia Nephrology LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183717 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,650.60 | 02/27/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LLC | An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy | No dispute reported | 06/30/2026 | 1190311547 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $152,482.17 | 02/25/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LAWRENCEVILLE BILLING OFFICE | A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease | No dispute reported | 06/30/2026 | 1214125226 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,282,747.36 | 02/24/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY RESEARCH INSTITUTE | A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care | No dispute reported | 06/30/2026 | 1190310532 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $791,454.90 | 02/17/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY RESEARCH INSTITUTE | An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy | No dispute reported | 06/30/2026 | 1190310536 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $107,768.60 | 01/28/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LAWRENCEVILLE BILLING OFFICE | An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3) | No dispute reported | 06/30/2026 | 1214124088 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $5,604.05 | 01/23/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LLC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY | No dispute reported | 06/30/2026 | 1225335379 |
| Principal investigator 1 | Genentech, Inc. | $10,842.00 | 01/22/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LLC | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211610818 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,867.80 | 01/22/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY RESEARCH INSTITUTE | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function | No dispute reported | 06/30/2026 | 1190310530 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $141.60 | 01/15/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY RESEARCH INSTITUTE | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy | No dispute reported | 06/30/2026 | 1190310540 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $230,446.46 | 01/11/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LAWRENCEVILLE | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) | No dispute reported | 06/30/2026 | 1214124960 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $32,488.85 | 01/03/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LLC | A PHASE 2/3, MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY | No dispute reported | 06/30/2026 | 1225335175 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $267,926.95 | 01/01/2025 | Non-covered Recipient Entity GEORGIA NEPHROLOGY LAWRENCEVILLE BILLING OFFICE | A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease | No dispute reported | 06/30/2026 | 1214124962 |